• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌:晚期癌症管理中新兴的可改变风险因素与治疗策略

Prostate Cancer: Emerging Modifiable Risk Factors and Therapeutic Strategies in the Management of Advanced Cancer.

作者信息

Bossio Sabrina, Urlandini Lidia, Perri Anna, Conforti Francesco, Aversa Antonio, Di Agostino Silvia, Rago Vittoria

机构信息

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.

出版信息

Life (Basel). 2024 Aug 30;14(9):1094. doi: 10.3390/life14091094.

DOI:10.3390/life14091094
PMID:39337878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11433263/
Abstract

Prostate cancer (PCa) is the third highest cause of cancer death in men. PCa is a very heterogeneous tumor form in terms of grade, phenotypes, and genetics, often accompanied by complex networks. PCa is characterized by slow growth that does not compromise the patient's quality of life, unlike more aggressive forms showing rapid growth and progression. Early diagnosis, even for the most aggressive forms, increases the possibilities of cure with less aggressive treatments and fewer side effects. However, it is important to know how to decrease the exposure to modifiable risk factors, including diet, sedentary life, smoking and alcohol, can represent an effective tool to reduce the incidence of PCa. In addition, the chronic exposure to environmental factors, most of which act as endocrine disruptors, is the focus of recent studies for their potential role in promoting the onset and progression of PCa. Although molecular therapies and clinical trials for biomarker identification have been introduced into the management of PCa, these still lag behind research performed in other solid tumors. This review provides an overview of the modifiable factors of PCa, linked to lifestyle and environmental pollutants, which together with the development of new therapeutic targets, can reduce the incidence of PCa and improve the quality of life of patients.

摘要

前列腺癌(PCa)是男性癌症死亡的第三大原因。就分级、表型和遗传学而言,PCa是一种非常异质性的肿瘤形式,常伴有复杂的网络。PCa的特点是生长缓慢,不会损害患者的生活质量,这与表现出快速生长和进展的更具侵袭性的肿瘤形式不同。即使对于最具侵袭性的形式,早期诊断也会增加采用侵袭性较小的治疗方法治愈且副作用较少的可能性。然而,重要的是要知道如何减少接触可改变的风险因素,包括饮食、久坐不动的生活方式、吸烟和饮酒,这可能是降低PCa发病率的有效手段。此外,长期接触环境因素,其中大多数作为内分泌干扰物,因其在促进PCa发生和进展中的潜在作用而成为近期研究的重点。尽管分子疗法和用于生物标志物识别的临床试验已被引入PCa的管理中,但这些仍落后于在其他实体瘤中进行的研究。本综述概述了与生活方式和环境污染物相关的PCa可改变因素,这些因素与新治疗靶点的开发一起,可以降低PCa的发病率并改善患者的生活质量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a56/11433263/09b8bba50455/life-14-01094-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a56/11433263/09b8bba50455/life-14-01094-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a56/11433263/09b8bba50455/life-14-01094-g001.jpg

相似文献

1
Prostate Cancer: Emerging Modifiable Risk Factors and Therapeutic Strategies in the Management of Advanced Cancer.前列腺癌:晚期癌症管理中新兴的可改变风险因素与治疗策略
Life (Basel). 2024 Aug 30;14(9):1094. doi: 10.3390/life14091094.
2
Underlying Features of Prostate Cancer-Statistics, Risk Factors, and Emerging Methods for Its Diagnosis.前列腺癌的基本特征-统计数据、风险因素和新的诊断方法。
Curr Oncol. 2023 Feb 15;30(2):2300-2321. doi: 10.3390/curroncol30020178.
3
Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions.前列腺癌管理:长期观念、21世纪初的流行趋势及三维解决方案
EPMA J. 2020 Jun 26;11(3):399-418. doi: 10.1007/s13167-020-00214-1. eCollection 2020 Sep.
4
Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU).最新证据表明,吸烟、运动和性行为是可改变的生活方式风险因素,会影响前列腺癌的发病、复发和进展:欧洲泌尿外科学会肿瘤泌尿外科学分会(ESOU)对文献的系统评价。
Eur Urol Focus. 2019 Sep;5(5):756-787. doi: 10.1016/j.euf.2018.02.007. Epub 2018 Mar 23.
5
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
6
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.高风险局限性和局部进展性前列腺癌的主要治疗方法的获益与风险:一项国际多学科系统评价。
Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4.
7
Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.代谢性疾病、药物和饮食因素对前列腺癌风险、复发和生存的影响:欧洲泌尿外科学会肿瘤泌尿学分会的系统评价。
Eur Urol Focus. 2019 Nov;5(6):1029-1057. doi: 10.1016/j.euf.2018.04.001. Epub 2018 Apr 13.
8
The Minderoo-Monaco Commission on Plastics and Human Health.美诺集团-摩纳哥基金会塑料与人体健康委员会
Ann Glob Health. 2023 Mar 21;89(1):23. doi: 10.5334/aogh.4056. eCollection 2023.
9
Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.前列腺特异性膜抗原的生物学特性与致命性前列腺癌及其治疗意义
Eur Urol Focus. 2022 Sep;8(5):1157-1168. doi: 10.1016/j.euf.2021.06.006. Epub 2021 Jun 22.
10
Biomarkers for determination prostate cancer: implication for diagnosis and prognosis.用于确定前列腺癌的生物标志物:对诊断和预后的意义。
Neoplasma. 2015;62(5):683-91. doi: 10.4149/neo_2015_082.

引用本文的文献

1
Aberrant expression of multiple γ-glutamyltransferases is associated with tumor progression and patient outcome in prostate cancers.多种γ-谷氨酰转移酶的异常表达与前列腺癌的肿瘤进展及患者预后相关。
Front Oncol. 2025 Feb 28;15:1518636. doi: 10.3389/fonc.2025.1518636. eCollection 2025.
2
Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers.Claudin 18.2并非前列腺癌靶向免疫治疗的理想生物标志物。
In Vivo. 2025 Mar-Apr;39(2):819-823. doi: 10.21873/invivo.13884.

本文引用的文献

1
New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer.用于转移性前列腺癌的靶向放射性核素治疗的新药。
Eur Urol Focus. 2024 Jul;10(4):514-517. doi: 10.1016/j.euf.2024.07.016. Epub 2024 Aug 13.
2
PSMA-based therapeutics for prostate cancer.基于 PSMA 的前列腺癌治疗药物。
Expert Opin Pharmacother. 2024 Jul;25(10):1405-1419. doi: 10.1080/14656566.2024.2385726. Epub 2024 Jul 31.
3
Early Prostate Cancer Deaths Among Men With Higher vs Lower Genetic Risk.具有较高遗传风险与较低遗传风险的男性中前列腺癌早期死亡的比较。
JAMA Netw Open. 2024 Jul 1;7(7):e2420034. doi: 10.1001/jamanetworkopen.2024.20034.
4
Ambient air pollution and urological cancer risk: A systematic review and meta-analysis of epidemiological evidence.大气污染与泌尿系统癌症风险:流行病学证据的系统评价与荟萃分析。
Nat Commun. 2024 Jun 15;15(1):5116. doi: 10.1038/s41467-024-48857-2.
5
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.PSCA-CAR T 细胞疗法治疗转移性去势抵抗性前列腺癌:一项 1 期试验。
Nat Med. 2024 Jun;30(6):1636-1644. doi: 10.1038/s41591-024-02979-8. Epub 2024 Jun 12.
6
PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?PSMA 靶向放射性核素治疗在现代核医学中的应用:过去、现在和未来?
Theranostics. 2024 May 13;14(8):3043-3079. doi: 10.7150/thno.92612. eCollection 2024.
7
Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer.靶向肿瘤微环境,一种前列腺癌的新治疗方法。
Prostate Cancer Prostatic Dis. 2024 Apr 2. doi: 10.1038/s41391-024-00825-z.
8
Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer.健康生活方式与癌症风险:可改变的癌症预防风险因素。
Nutrients. 2024 Mar 11;16(6):800. doi: 10.3390/nu16060800.
9
Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses.前列腺癌的风险因素:前瞻性观察研究和孟德尔随机分析的伞状综述。
PLoS Med. 2024 Mar 15;21(3):e1004362. doi: 10.1371/journal.pmed.1004362. eCollection 2024 Mar.
10
Impact of a Mediterranean diet on prevention and management of urologic diseases.地中海饮食对泌尿疾病的预防和治疗的影响。
BMC Urol. 2024 Feb 26;24(1):48. doi: 10.1186/s12894-024-01432-9.